Expression of GnTIII in a recombinant anti‐CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII
Abstract
The gene encoding the rat glycosylation enzyme β1–4‐N‐acetylglucosaminyltransferase III (GnTIII) was cloned and coexpressed in a recombinant production Chinese hamster ovary (CHO) cell line expressing a chimeric mouse/human anti‐CD20 IgG1 antibody. The new cell lines expressed high levels of antibody and have growth kinetics similar to that of the parent. Relative QPCR showed the cell lines to express varying levels of mRNA. High‐performance liquid chromatography (HPLC) analysis showed the enzyme to have added bisecting N‐acetylglucosamine (GlcNAc) residues in most (48% to 71%) of the N‐linked oligosaccharides isolated from antibody preparations purified from the cell lines. In an ADCC assay the new antibody preparations promoted killing of CD20‐positive target cells at approximately 10‐ to 20‐fold lower concentrations than the parent. This activity was blocked using an anti‐FcγRIII antibody, supporting the role of FcγRIII binding in this increase. In addition, cell binding assays showed the modified antibody bound better to FcγRIII‐expressing cells. The increase in ADCC activity is therefore likely due to an increased affinity of the modified antibody for the FcγRIII receptor. © 2001 John Wiley & Sons, Inc. Biotechnol Bioeng 74: 288–294, 2001.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Since expression of GnTIII blocks fucosylation, CHO cells were engineered with both GnTIII and Golgi mannosidase II (ManII) for IgG production.
“Since expression of the β1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase III (GnTIII) blocks fucosylation, CHO cells were engineered with both GnTIII and Golgi mannosidase II (ManII) for IgG production (Davies et al., 2001;Ferrara et al., 2006).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Davies et al., 2001
Cites
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996 · see citing works
Self-citationMaloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,732 · see citing works
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · see citing works
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 572 · see citing works
Narasimhan, S. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34010-9 · Cited by 227 · see citing works
Lifely, M. R., Hale, C., Boyce, S., Keen, M., & Phillips, J. (1995) · Glycobiology · doi:10.1093/glycob/5.8.813 · Cited by 173 · see citing works
Antibody Engineering at the Millennium
Gavilondo, J., & Larrick, J. W. (2000) · BioTechniques · doi:10.2144/00291ov01 · Cited by 113 · see citing works
Campbell, C. E., & Stanley, P. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90704-0 · Cited by 100 · see citing works
Bragonzi, A., Distefano, G., Buckberry, L. D., Acerbis, G., Foglieni, C., Lamotte, D., Campi, G., Marc, A., Soria, M. R., Jenkins, N., et al. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(00)00023-4 · Cited by 96 · see citing works
Phosphorylation of the CD20 Phosphoprotein in Resting B Lymphocytes
Valentine, M. A., Meier, K. E., Rossie, S. S., & Clark, E. A. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60461-2 · Cited by 95 · see citing works
Tetracycline-Regulated overexpression of glycosyltransferases in Chinese hamster ovary cells
Uma�a, P., Jean-Mairet, J., & Bailey, J. E. (1999) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19991205)65:5 · Cited by 45 · see citing works
Engineering Antibodies for the Clinic
Holliger, P., & Bohlen, H. (1999) · Cancer and Metastasis Reviews · doi:10.1023/a:1006314421941 · Cited by 21 · see citing works
Ralph, P., Saiki, O., MAURER, D. H., & Welte, K. (1983) · Immunology Letters · doi:10.1016/0165-2478(83)90049-4 · Cited by 11 · see citing works
Metabolic Engineering of N-Linked Glycoform Synthesis Systems in Chinese Hamster Ovary (CHO) Cells
Bailey, J. E., Umaña, P., Minch, S. L., Harrington, M. G., Pagé, M., & Sburlati, A. R. (1997) · Springer eBooks · doi:10.1007/978-94-011-5404-8_78 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · see citing works
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · see citing works
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,007 · see citing works
Monoclonal Antibodies in Cancer Therapy
Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 845 · see citing works
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · see citing works
“Subsequently, two groups engineered the CHO cell line to express the GnTIII enzyme that adds bisecting N -acetylglucosamine residues, and demonstrated that ADCC improved by two or more orders of magnitude for a rituximab-like produc”
BackgroundCell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739 · see citing works
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669 · see citing works
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2005) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526 · see citing works
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal‐Céligny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 521 · see citing works
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521 · see citing works
Heterogeneity of Monoclonal Antibodies
Liu, H., Gaza‐Bulseco, G., Faldu, D., Chumsae, C. M., & Sun, J. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21180 · Cited by 482 · see citing works
Birch, J. R., & Racher, A. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.006 · Cited by 477 · see citing works
Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 469 · see citing works
Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review
Maverakis, E. M., Kim, K., Shimoda, M., Gershwin, M. E., Patel, F., Wilken, R., Raychaudhuri, S. P., Ruhaak, L. R., & Lebrilla, C. B. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.12.002 · Cited by 456 · see citing works
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · see citing works
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 405 · see citing works
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393 · see citing works
Expression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386 · see citing works
Recombinant protein expression for therapeutic applications
Andersen, D. C., & KRUMMEN, L. A. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00300-2 · Cited by 365 · see citing works
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 329 · see citing works
Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai, N., & Shitara, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2068 · Cited by 327 · see citing works
The Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 324 · see citing works
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 315 · see citing works
Mass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2008) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 318 · see citing works
The art of CHO cell engineering: A comprehensive retrospect and future perspectives
Fischer, S., Handrick, R., & Otte, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.10.015 · Cited by 314 · see citing works
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294 · see citing works
Enzymes in the Synthesis of Glycoconjugates
Schmaltz, R. M., Hanson, S. R., & Wong, C. (2011) · Chemical Reviews · doi:10.1021/cr200113w · Cited by 284 · see citing works
Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
Matsumiya, S., Yamaguchi, Y., Saito, J., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K., & Kato, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.034 · Cited by 278 · see citing works
Vučković, F., Krištić, J., Gudelj, I., Teruel, M., Keser, T., Pezer, M., Pučić‐Baković, M., Štambuk, J., Trbojević‐Akmačić, I., Barrios, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39273 · Cited by 270 · see citing works
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 260 · see citing works
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236 · see citing works
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236 · see citing works
Pharmacological significance of glycosylation in therapeutic proteins
Li, H., & d′Anjou, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.009 · Cited by 232 · see citing works
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
Hudak, J. E., & Bertozzi, C. R. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.010 · Cited by 228 · see citing works
N-glycomic biomarkers of biological aging and longevity: A link with inflammaging
Dall’Olio, F., Vanhooren, V., Chen, C. C., Slagboom, P. E., Wuhrer, M., & Franceschi, C. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.02.002 · Cited by 231 · see citing works
Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227 · see citing works
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 218 · see citing works
Fc Glycan-Mediated Regulation of Placental Antibody Transfer
Jennewein, M. F., Goldfarb, I. T., Dolatshahi, S., Cosgrove, C., Noelette, F. J., Krykbaeva, M., Das, J., Sarkar, A., Gorman, M. J., Fischinger, S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.044 · Cited by 209 · see citing works
Berlec, A., & Štrukelj, B. (2013) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-013-1235-0 · Cited by 212 · see citing works
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies
Mould, D. R., & Green, B. (2010) · BioDrugs · doi:10.2165/11530560-000000000-00000 · Cited by 207 · see citing works
Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206 · see citing works
Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease
Pagan, J. D., Kitaoka, M., & Anthony, R. M. (2017) · Cell · doi:10.1016/j.cell.2017.11.041 · Cited by 203 · see citing works
High-Throughput IgG Fc N-Glycosylation Profiling by Mass Spectrometry of Glycopeptides
Pučić‐Baković, M., Selman, M. H. J., Hoffmann, M., Rudan, I., Campbell, H., Deelder, A. M., Lauc, G., & Wuhrer, M. (2013) · Journal of Proteome Research · doi:10.1021/pr300887z · Cited by 204 · see citing works
A common glycan structure on immunoglobulin G for enhancement of effector functions
Lin, C., Tsai, M.-H., Li, S., Tsai, T.-I., Chu, K., Liu, Y.-C., Lai, M.-Y., Wu, C.-Y., Tseng, Y.-C., Shivatare, S. S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513456112 · Cited by 200 · see citing works
Novel roles for the IgG Fc glycan
Anthony, R. M., Wermeling, F., & Ravetch, J. V. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06305.x · Cited by 186 · see citing works
Niwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187 · see citing works
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S. T., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 186 · see citing works
Antibody glycosylation in inflammation, disease and vaccination
Alter, G., Ottenhoff, T. H. M., & Joosten, S. A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.003 · Cited by 186 · see citing works
Holland, M., Yagi, H., Takahashi, N., Kato, K., Savage, C. O. S., Goodall, D. M., & Jefferis, R. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.11.021 · Cited by 184 · see citing works
Zhou, Q., Shankara, S., Roy, A. J., Qiu, H., Estes, S. D., McVie-Wylie, A. J., Culm-Merdek, K., Park, A., Pan, C. Q., & Edmunds, T. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 185 · see citing works
Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179 · see citing works
Masuda, K., Kubota, T., Kaneko, E., Iida, S., Wakitani, M., Kobayashi-Natsume, Y., Kubota, A., Shitara, K., & Nakamura, K. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.02.005 · Cited by 179 · see citing works
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178 · see citing works
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175 · see citing works
Mori, K., Kuni‐Kamochi, R., Yamane‐Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, R., Iida, S., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20326 · Cited by 174 · see citing works
Butler, M. (2005) · Cytotechnology · doi:10.1007/s10616-005-4537-x · Cited by 169 · see citing works
Zou, G., Ochiai, H., Huang, W., Yang, Q., Li, C., & Wang, L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208390n · Cited by 167 · see citing works
Fc-Glycosylation of IgG1 is Modulated by B-cell Stimuli
Wang, J., Balog, C. I. A., Stavenhagen, K., Koeleman, C. A. M., Scherer, H. U., Selman, M. H. J., Deelder, A. M., Huizinga, T. W. J., Toes, R. E. M., & Wuhrer, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004655 · Cited by 162 · see citing works
Glycosylation: impact, control and improvement during therapeutic protein production
Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2013) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 155 · see citing works
A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis
Karsten, C. B., Mehta, N., Shin, S. A., Diefenbach, T. J., Slein, M. D., Karpinski, W., Irvine, E. B., Broge, T. A., Suscovich, T. J., & Alter, G. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.05.006 · Cited by 154 · see citing works
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 152 · see citing works
Saxena, A., & Wu, D. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00580 · Cited by 150 · see citing works
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination
Mahan, A. E., Jennewein, M. F., Suscovich, T. J., Dionne, K., Tedesco, J., Chung, A. W., Streeck, H., Pau, M. G., Schuitemaker, H., Francis, D., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005456 · Cited by 149 · see citing works
Boosting therapeutic potency of antibodies by taming Fc domain functions
Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 142 · see citing works
Emerging Technologies for Making Glycan-Defined Glycoproteins
Wang, L., & Lomino, J. V. (2011) · ACS Chemical Biology · doi:10.1021/cb200429n · Cited by 137 · see citing works
Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination
Selman, M. H. J., de Jong, S. E., Soonawala, D., Kroon, F. P., Adégnika, A. A., Deelder, A. M., Hokke, C. H., Yazdanbakhsh, M., & Wuhrer, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014563 · Cited by 136 · see citing works
Boune, S., Hu, P., Epstein, A. L., & Khawli, L. A. (2020) · Antibodies · doi:10.3390/antib9020022 · Cited by 138 · see citing works
Engineering mammalian cells in bioprocessing – current achievements and future perspectives
Lim, Y., Wong, N. S. C., Lee, Y. Y., Ku, S. C. Y., Wong, D. C. F., & Yap, M. G. S. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090363 · Cited by 134 · see citing works
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 131 · see citing works
Preithner, S., Elm, S., Lippold, S., Locher, M., Wolf, A., da Silva, A. J., Baeuerle, P. A., & Prang, N. S. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.010 · Cited by 131 · see citing works
Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 128 · see citing works
The regulatory power of glycans and their binding partners in immunity
Johnson, J. L., Jones, M. B., Ryan, S. O., & Cobb, B. A. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.01.006 · Cited by 125 · see citing works
Altered N‐glycosylation profiles as potential biomarkers and drug targets in diabetes
Rudman, N., Gornik, O., & Lauc, G. (2019) · FEBS Letters · doi:10.1002/1873-3468.13495 · Cited by 124 · see citing works
IgG glycan patterns are associated with type 2 diabetes in independent European populations
Lemmers, R. F. H., Vilaj, M. Ć., Urda, D., Agakov, F. V., Šimurina, M., Klarić, L., Rudan, I., Campbell, H. J., Hayward, C., Wilson, J., et al. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.06.020 · Cited by 121 · see citing works
Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Golay, J., Andrea, A. E., & Cattaneo, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929895 · Cited by 120 · see citing works
Regulated Glycosylation Patterns of IgG during Alloimmune Responses against Human Platelet Antigens
Wuhrer, M., Porcelijn, L., Kapur, R., Koeleman, C. A. M., Deelder, A. M., de Haas, M., & Vidarsson, G. (2008) · Journal of Proteome Research · doi:10.1021/pr800651j · Cited by 119 · see citing works
Antibody Glycosylation and Inflammation
Shade, K.-T., & Anthony, R. M. (2013) · Antibodies · doi:10.3390/antib2030392 · Cited by 120 · see citing works
The sweet tooth of biopharmaceuticals: Importance of recombinant protein glycosylation analysis
Lingg, N., Zhang, P., Song, Z., & Bardor, M. (2012) · Biotechnology Journal · doi:10.1002/biot.201200078 · Cited by 114 · see citing works
Decoding sugar functions by identifying target glycoproteins
Taniguchi, N., Miyoshi, E., Jianguo, G., Honke, K., & Matsumoto, A. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.08.011 · Cited by 111 · see citing works
Kamoda, S., Ishikawa, R., & Kakehi, K. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.08.028 · Cited by 112 · see citing works
Mahan, A. E., Tedesco, J., Dionne, K., Baruah, K., Cheng, H. D., Jager, P. L. D., Barouch, D. H., Suscovich, T. J., Ackerman, M. E., Crispin, M., et al. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.12.004 · Cited by 108 · see citing works
The clinical pharmacology of therapeutic monoclonal antibodies
Roskos, L. K., Davis, C., & Schwab, G. M. (2004) · Drug Development Research · doi:10.1002/ddr.10346 · Cited by 102 · see citing works
Holtsberg, F. W., Shulenin, S., Vu, H., Howell, K. A., Patel, S. J., Gunn, B. M., Karim, M. M., Lai, J. R., Frei, J. C., Nyakatura, E. K., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02171-15 · Cited by 99 · see citing works
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Kellner, C., Otte, A., Cappuzzello, E., Klausz, K., & Peipp, M. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479980 · Cited by 99 · see citing works
Bynum, M. A., Yin, H., Felts, K. A., Lee, Y. M., Monell, C. R., & Killeen, K. (2009) · Analytical Chemistry · doi:10.1021/ac901326u · Cited by 98 · see citing works
Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis
HOLLAND, M., Takada, K., OKUMOTO, T., Takahashi, N., Kato, K., Adu, D., Ben‐Smith, A., Harper, L., Savage, C. O. S., & Jefferis, R. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01864.x · Cited by 98 · see citing works
Wei, Y., Li, C., Huang, W., Li, B., Strome, S. E., & Wang, L. (2008) · Biochemistry · doi:10.1021/bi800874y · Cited by 98 · see citing works
Kemna, M. J., Plomp, R., van Paassen, P., Koeleman, C. A. M., Jansen, B. C., Damoiseaux, J. G. M. C., Tervaert, J. W. C., & Wuhrer, M. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.033 · Cited by 97 · see citing works
Sialylation as an Important Regulator of Antibody Function
Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 97 · see citing works
Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
Jung, S. T., Kang, T. H., Kelton, W., & Georgiou, G. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.03.002 · Cited by 97 · see citing works
Antibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 94 · see citing works
Engineering Cells for Cell Culture Bioprocessing – Physiological Fundamentals
Seth, G., Hossler, P., Yee, J. C., & Hu, W. (2006) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_017 · Cited by 94 · see citing works
FcγR: The key to optimize therapeutic antibodies?
Sibéril, S., Dutertre, C., Fridman, W. H., & Teillaud, J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.12.003 · Cited by 92 · see citing works
Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis
Kamoda, S., Nomura, C., Kinoshita, M., Nishiura, S., Ishikawa, R., Kakehi, K., Kawasaki, N., & Hayakawa, T. (2004) · Journal of Chromatography A · doi:10.1016/s0021-9673(04)01399-8 · Cited by 86 · see citing works
IgG glycans in health and disease: Prediction, intervention, prognosis, and therapy
Shkunnikova, S., Mijakovac, A., Sironić, L., Hanić, M., Lauc, G., & Kavur, M. M. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108169 · Cited by 83 · see citing works
Chartrain, M. M., & Chu, L. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786367 · Cited by 83 · see citing works
Cartron, G., Trappe, R. U., Solal‐Céligny, P., & Hallek, M. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1292 · Cited by 84 · see citing works
Protein Glycoengineering: An Approach for Improving Protein Properties
Ma, B., Guan, X., Li, Y., Shang, S., Li, J., & Tan, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00622 · Cited by 81 · see citing works
Modulating Antibody Functionality in Infectious Disease and Vaccination
Gunn, B. M., & Alter, G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.09.002 · Cited by 80 · see citing works
- Authors
- Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M.
- Corresponding author
- Reff, Mitchell
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2001-06-06
- Volume
- 74
- Issue
- 4
- Pages
- 288-294
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2059347528
- Cited by
- 327
- References
- 14
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 11 · 2023: 8 · 2022: 13 · 2021: 14 · 2020: 12 · 2019: 14 · 2018: 18 · 2017: 17 · 2016: 21 · 2015: 13 · 2014: 17 · 2013: 20 · 2012: 18
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology and Bioengineering (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Keywords
- anti-CD20 monoclonal antibody, antibody glycosylation, bisecting N-acetylglucosamine, N-glycans, antibody-drug conjugates, antibody-dependent cellular cytotoxicity, FcγRIII, CHO cell expression
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Carbohydrate Sequence, Cell Division, Chromatography, High Pressure Liquid, Cloning, Molecular, Enzyme-Linked Immunosorbent Assay, Genetic Engineering, Glycosylation, Cricetinae, Immunoglobulin G, Molecular Sequence Data, Recombinant Proteins, RNA, Messenger, CHO Cells, N-Acetylglucosaminyltransferases, Receptors, IgG, Antigens, CD20, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
